{"id":970911,"date":"2026-06-04T17:38:29","date_gmt":"2026-06-04T21:38:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zts-shareholder-alert-zoetis-inc-securities-class-action-lawsuit-investors-should-contact-suewallst\/"},"modified":"2026-06-04T17:38:29","modified_gmt":"2026-06-04T21:38:29","slug":"zts-shareholder-alert-zoetis-inc-securities-class-action-lawsuit-investors-should-contact-suewallst","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zts-shareholder-alert-zoetis-inc-securities-class-action-lawsuit-investors-should-contact-suewallst\/","title":{"rendered":"ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit – Investors Should Contact SueWallSt"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Time-Sensitive: Allegations Focus on Concealed FDA Safety Warnings and Competitive Market Share Erosion That Cost ZTS Investors Billions<\/i>\n <\/p>\n

\n NEW YORK<\/span>, June 4, 2026<\/span> \/PRNewswire\/ — SueWallSt alerts investors in Zoetis Inc. (NYSE: ZTS) of a pending securities class action. Class Period: January 14, 2025 through May 6, 2026. Check if you can recover your investment losses<\/a>\u00a0or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com<\/a>\u00a0| (888) SueWallSt.<\/p>\n

\n

\n \"SueWallSt.com\"\n <\/p>\n<\/p><\/div>\n

Zoetis shares collapsed 21.5%, a loss of nearly $24 per share, as the market learned the Company’s Companion Animal franchise was under far greater pressure than management disclosed. The Court has set July 27, 2026 as the deadline to apply for lead plaintiff appointment.<\/p>\n

\n The Alleged<\/span> FDA Safety Concealment and Its Market Consequences<\/b>\n <\/p>\n

In December 2024, the FDA issued a “Dear Veterinarian” letter describing severe adverse neurological events in dogs treated with Librela, including seizures, paresis, recumbency, and death. The lawsuit asserts that management minimized the letter’s significance to investors, characterizing it as “terribly helpful” and “consistent with what we’ve been telling them.” In reality, the action claims, veterinarian confidence in prescribing Librela was deteriorating sharply, directly undermining the growth trajectory management promoted.<\/p>\n

A label update warning of neurological and mobility-related events was subsequently applied to Librela. Rather than disclose the prescribing slowdown this triggered, the Company allegedly<\/span> continued to tout “very strong satisfaction levels” and “record penetration” among clinics.<\/p>\n

\n Elanco’s Competitive Threat and the Dermatology and Parasiticide Erosion<\/b>\n <\/p>\n

The lawsuit contends that management concealed the pace at which Elanco’s newly launched therapies were capturing market share:<\/p>\n